Rituximab for Rheumatoid Arthritis Following TNF-alpha Inhibitor Associated Splenic Tuberculosis
Journal of Rheumatic Diseases
; : 108-112, 2013.
Article
en Ko
| WPRIM
| ID: wpr-50813
Biblioteca responsable:
WPRO
ABSTRACT
One of the most important adverse effects of a tumor necrosis factor (TNF)-alpha inhibitor is the reactivation of tuberculosis. Most of them occur in the lung, but sometimes they can be found in other organs. Moreover, the proper management of active rheumatoid arthritis (RA) in patients with anti-TNF-alpha associated tuberculosis is still in debate. We present the case of a seropositive RA patient who showed good response with rituximab, an anti-CD20 monoclonal antibody, after developing splenic tuberuculosis, following treatment with TNF-alpha inhibitor. Confirming a diagnosis of splenic tuberculosis is difficult and can be delayed due to its nonspecific symptoms and rare occurrence. This case suggests that splenic tuberculosis should be doubted in RA patients treated with TNF-alpha inhibitor, and that rituximab may be considered as an alternative treatment option in RA patients with anti-TNF-alpha associated tuberculosis.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Artritis Reumatoide
/
Tuberculosis
/
Tuberculosis Esplénica
/
Factor de Necrosis Tumoral alfa
/
Anticuerpos Monoclonales de Origen Murino
/
Rituximab
/
Pulmón
Límite:
Humans
Idioma:
Ko
Revista:
Journal of Rheumatic Diseases
Año:
2013
Tipo del documento:
Article